Fig. 2: Representative quinoline SARS-CoV-2 PLpro inhibitors.
From: Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
a Chemical structure and in vitro activities of Jun12682, Jun12665, and Jun13338. b Chemical structures and in vitro activities of quinoline analogs with diverse amine substituents. IC50, half maximal inhibitory concentration in the FRET enzymatic assay; Ki, inhibitory constant in the FRET enzymatic assay; CC50: half maximal toxicity concentration in Vero cells, CC50 values are mean ± S.D. of three technical repeats; EC50, half maximal effective concentration in the FlipGFP and antiviral assays, EC50 values are mean ± standard deviation of three technical repeats; T1/2, half-life in mouse liver microsomal stability assay. Source data are provided as a source data file.
